Lupin announces new partnership
BALTIMORE — Lupin Pharmaceuticals announced on Monday a partnership with Phil, Inc., which will help deliver cost-effective next-generation access solutions for patients who are prescribed Solosec (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec is the only single 2g oral dose therapy for the most common vaginal infection
